Table 2.
Demographic and Disease Characteristics of All Enrolled Patients Comparing Patients who failed to maintain Clinical Inactive Disease in the First 6 months (“Not evaluable”) to those maintained CID for the First 6 Months (“Evaluable”).
| All Patients | Not evaluable | Evaluable | P value** | |
|---|---|---|---|---|
| No (%) | No. (%) * | No. (%)* | ||
| Total | 130 (100%) | 24 (18%) | 106 (82%) | -- |
| Gender | 0.03 | |||
| Females | 97 (75%) | 22 (92%) | 75 (71%) | |
| Males | 33 (25%) | 2 (8%) | 31 (29%) | |
| Race | 0.38 | |||
| Caucasian | 122 (94%) | 24 (100%) | 98 (92%) | |
| African American | 7 (5%) | 0 | 7 (7%) | |
| Asian | 1 (1%) | 0 | 1 (1%) | |
| JIA Diagnosis | 0.04 | |||
| Extended oligo | 18 (14%) | 1 (4%) | 17 (16%) | |
| RF positive poly | 15 (11%) | 6 (25%) | 9 (8%) | |
| RF negative poly | 97 (75%) | 17 (71%) | 80 (75%) | |
| ANA status (N = 103) | 0.39 | |||
| Positive | 63 (50%) | 10 (42%) | 53 (51%) | |
| Negative | 64 (50%) | 14 (58%) | 50 (49%) | |
| RF status (N = 104) | 0.02 | |||
| Positive | 15 (12%) | 6 (26%) | 9 (9%) | |
| Negative | 112 (88%) | 17 (74%) | 95 (91%) | |
| Concurrent MTX | 0.16 | |||
| Yes | 54 (42%) | 13 (54%) | 41 (39%) | |
| No | 76 (58%) | 11 (46%) | 65 (61%) | |
| Anti-TNF agent | 0.04 | |||
| etanercept | 101 (78%) | 14 (58%) | 87 (82%) | |
| adalimumab | 22 (17%) | 8 (33%) | 14 (13%) | |
| infliximab | 7 (5%) | 2 (8%) | 5 (5%) |
| Mean (std) | Mean (std) | Mean (std) | P value*** | |
|---|---|---|---|---|
| Median (Q1, Q3) | Median (Q1, Q3) | Median (Q1, Q3) | ||
| Age at enrollment (yrs) | 11.16 (4.48) | 11.13 (4.39) | 11.16 (4.52) | 0.98 |
| 11.49 (6.79, 14.77) | 10.8 (7.69, 14.98) | 11.65 (6.68, 14.72) | ||
| Age at disease onset (yrs) | 6.05 (4.57) | 6.21 (4.50) | 6.01 (4.61) | 0.85 |
| 4.48 (2.01, 9.74) | 4.64 (2.25, 9.79) | 4.24 (2.00, 9.70) | ||
| Age at diagnosis (yrs) | 6.58 (4.65) | 6.92 (4.68) | 6.5 (4.67) | 0.69 |
| 5.4 (2.44, 10.21) | 5.78 (2.73, 10.93) | 5.33 (2.34, 10.21) | ||
| Disease duration at enrollment (yrs) | 5.11 (3.81) | 4.75 (3.84) | 5.18 (3.82) | 0.63 |
| 3.89 (2.28, 6.51) | 3.72 (2.06, 5.54) | 3.98 (2.39, 6.56) | ||
| Age, first occurrence of CID (yrs) | 10.02 (4.61) | 9.73 (4.42) | 10.09 (4.67) | 0.73 |
| 9.94 (6.27, 13.97) | 9.09 (6.28, 14.36) | 10.13 (6.27, 13.87) | ||
| Time from disease onset to first occurrence of CID (mos) | 3.94 (3.44) | 3.32 (3.37) | 4.08 (3.45) | 0.34 |
| 2.68 (1.48, 5.36) | 2.29 (1.49, 3.46) | 2.88 (1.47, 5.8) | ||
| Time from first occurrence of CID to baseline (yrs) | 1.15 (1.77) | 1.40 (1.91) | 1.10 (1.74) | 0.45 |
| 0.48 (0.18, 1.49) | 0.50 (0, 2.35) | 0.48 (0.19, 1.45) | ||
| Duration of anti- TNF (yrs) | 2.48 (1.81) | 2.12 (1.60) | 2.55 (1.84) | 0.33 |
| 1.87 (1.30, 3.09) | 1.70 (1.05, 2.74) | 1.9 (1.32, 3.09) | ||
| MTX dosage (mg/kg) | 0.44 (0.21) | 0.39 (0.24) | 0.46 (0.20) | 0.28 |
| 0.42 (0.27, 0.60) | 0.26 (0.24, 0.51) | 0.47 (0.30, 0.60) |
Patients “who failed” includes both those who were unable to maintain clinical inactive disease in first 6 months and those who flared within 8 months after stopping anti-TNF therapy; those who “did not fail” includes only those who maintained clinical inactive disease for first 6 months and did not flare for 8 months after stopping anti-TNF therapy.
P value based upon Chi square comparison of number who flared vs. not flared between strata of individual variables.
P value based upon Student T test comparison of group means between two columns
Note: 3 ANA results unknown; 2 RF results unknown (in order to be included in the analysis the 2 patients with unknown RF results were considered to be RF (−); One Age at first occurrence of CID value unknown.